Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
domingo, 30 de noviembre de 2025
Does Screening Interval Matter? Annual Mammograms Tied to Better Survival in Breast Cancer Maurie Markman, MD ++++++ +++ +++
Trending in November
Proton vs Photon RT in Breast Cancer: Which Is Better?
https://www.medscape.com/viewarticle/proton-vs-photon-rt-breast-cancer-which-better-2025a1000v0g?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Annual Screening Boosts Breast Cancer Survival
https://www.medscape.com/viewarticle/does-screening-interval-matter-annual-mammograms-tied-better-2025a1000sgu?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Routine Liquid Biopsies Could Cut Advanced Cancer Diagnoses
https://www.medscape.com/viewarticle/routine-liquid-biopsies-could-cut-advanced-cancer-diagnoses-2025a1000vsm?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Rediscovering Purpose in the Hardest Moments of Cancer Care
https://www.medscape.com/viewarticle/rediscovering-purpose-hardest-moments-cancer-care-2025a1000tt1?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
How to Identify Cancer in Patients With Nonspecific Symptoms
https://www.medscape.com/viewarticle/how-identify-cancer-patients-nonspecific-symptoms-2025a1000vn0?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
The Cancer Misinformation Train: When Influencers Co-Opt Care
https://www.medscape.com/viewarticle/cancer-misinformation-train-when-influencers-co-opt-care-2025a1000utj?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Also of Interest
Rethinking Ribociclib: Is 400 mg Noninferior to 600 mg for MBC?
https://www.medscape.com/viewarticle/rethinking-ribociclib-400-mg-noninferior-600-mg-metastatic-2025a1000tt2?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Novel Agents Transform Double-Refractory CLL Care
https://www.medscape.com/viewarticle/novel-agents-transform-double-refractory-chronic-lymphocytic-2025a1000jhf?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Is This Drug Combo the Future of CLL?
https://www.medscape.com/viewarticle/this-drug-combo-future-chronic-lymphocytic-leukemia-care-2025a1000rdh?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
US Drug Spotlight
Capivasertib
https://reference.medscape.com/drug/truqap-capivasertib-4000384?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Rituximab
https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
Acalabrutinib
https://reference.medscape.com/drug/calquence-acalabrutinib-1000209?ecd=mkm_ret_251130_mscpmrk_onc_top-content_etid7912865&uac=148436CN&impID=7912865
No hay comentarios:
Publicar un comentario